Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Schematic illustration of intracellular insulin signalling (aPKC: atypical Protein-Kinase C, eNOS: endothelial Nitric Oxide Synthase, ET1: Endothelin 1, FOX01: Forkhead Box01, IRS: Insulin Receptor Substrate, MAPK: Mitogen Activated Proteinkinase, MEK: Mitogen Activated Proteinkinase Kinase, NO: Nitric Oxide, PDK: Phosphoinositide-Dependent Kinase, PI3K: Phosphatidylinostol 3 Kinase, RAS, RAF: Proto-Oncogenes, SHC: Adapter Protein; adapted to [6]).](https://figures.cochat.ai/paper-figures/e59842cfba2b418699b2b8139ce25a4e/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-2.jpg)
![Figure 3 Postprandial proinsulin/insulin ratio in patients treated with sulfonylurea, insulin Glargine, or DPP-IV inhibitors compared to nondiabetic healthy controls (*: P < 0.05 versus nondiabetic controls adapted to [67]).](https://figures.cochat.ai/paper-figures/0793e9c9c9994ab290ff85428a4e2480/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-3.jpg)
![Figure 4 Schematic illustration of GLP-1-receptor-dependent and GLP-1-receptor-independent pathways in the signalling of GLP-1 associated cardiovascular effects (PI3K: phosphatidylinositol 3 kinase; cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PKB: protein kinase B, GSK3ß: glycogen synthase kinase 3 beta, MEK1/2: components of the MAP kinase cascade, ERK: extracellular-signal-regulated kinase, NO: nitric oxide, eNOS: endothelial nitric oxide synthase, cGMP: cyclic guanosine monophosphate, PKG: protein kinase G; adapted to [69]).](https://figures.cochat.ai/paper-figures/036b615ae95d4bccba96f64637f740ef/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, GLP-1 analogues also appear to decrease the risk of cardiovascular pathology in patients, according to some studies, and preliminary data suggest they do so to a greater degree than other oral glucose-lowering drugs.262,275–277”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [277]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · cited 2×
“Following its release from the L-cells into the blood stream, GLP-1 [7– 36] is quickly cleaved by the enzyme dipeptidyl-peptidaseIV (DPP-IV) into the split product GLP-1 [9–39], which results in a half-life time of GLP-1 [7–39] of only 2 minutes.”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“Following its release from the L-cells into the blood stream, GLP-1 [7– 36] is quickly cleaved by the enzyme dipeptidyl-peptidaseIV (DPP-IV) into the split product GLP-1 [9–39], which results in a half-life time of GLP-1 [7–39] of only 2 minutes.”
BackgroundAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · cited 1×
“As pointed out by Zilversmit many years ago, atherosclerosis could be considered to be a prandial phenomenon [86].”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Research works printed but not linked: 4
- 2005, Panminerva Medica, 47, 201
- 10.1185/030079907X253870 · doi:10.1185/030079907x253870 · Paper page
- 1993, American Journal of Physiology, 265, L374
- 2009, European Heart Journal, 30, 917
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 149
“GLP-1 may also have a direct modulatory effect on several cardiovascular pathways involved in atherogenesis [186].”
BackgroundSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Mahmoud, A. M., Wilkinson, F. L., Jones, A. M., Wilkinson, J. A., Romero, M., Duarte, J., & Alexander, M. Y. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.08.013 · Cited by 74
“to an atherogenic milieu, contributing to endothelial dysfunction [6].”
Sottero, B., Gargiulo, S., Russo, I., Barale, C., Poli, G., & Cavalot, F. L. (2015) · Medicinal Research Reviews · doi:10.1002/med.21349 · Cited by 83
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
He, W., Yu, S., Wang, L., He, M., Cao, X., Li, Y., & Xiao, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.032 · Cited by 58
Alssema, M., Rijkelijkhuizen, J. M., Holst, J. J., Teerlink, T., Scheffer, P. G., Eekhoff, E. M. W., Gastaldelli, A., Mari, A., Hart, L. M., Nijpels, G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0487 · Cited by 56
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
“Unau Health | Lippincott Williams & Wilki risk factors such as weight, systolic blood pressure, and lipid profile [8].”
BackgroundThe endothelium in diabetes: Its role in insulin access and diabetic complications
Kolka, C. M., & Bergman, R. N. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9233-5 · Cited by 59
“GLP-1 has been shown to have effects on eNOS phosphorylation, leading to increased NO production and flow mediated vasodilatation [58, 59].”
Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
“Previous studies showed possible beneficial effects on endothelial function and the CV system through direct effects mediated through GLP-1 receptor-dependent and through independent mechanisms [56].”
BackgroundBerndt-Zipfel, C., Michelson, G., Dworak, M., Mitry, M., Löffler, A., Pfützner, A., & Forst, T. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-59 · Cited by 38
Self-citationLim, D.-M., Park, K.-Y., Hwang, W.-M., Kim, J.-Y., & Kim, B.-J. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4279 · Cited by 37
Diabetic Dyslipidemia: From Evolving Pathophysiological Insight to Emerging Therapeutic Targets
Ng, D. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.062 · Cited by 38
Wei, F., Sun, X., Zhao, Y., Zhang, H., Diao, Y., & Liu, Z. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0300-0 · Cited by 32
“[7].”
Li, Y., Huang, C., Fu, W., Zhang, H., Lao, Y., Zhou, H., Tan, H., & Xu, H. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112645 · Cited by 28
GLP-1 receptor agonists: A review of glycemic benefits and beyond
Clark, L. (2024) · JAAPA · doi:10.1097/01.jaa.0001007388.97793.41 · Cited by 28
Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
Singh, S. B., Bhat, J., & Wang, P. H. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0327-1 · Cited by 23
Gilstrap, L. G., Blair, R. A., Huskamp, H. A., Zelevinsky, K., & Normand, S. T. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5411 · Cited by 24
An update on ocular effects of antidiabetic medications
Sadeghi, E., Rahmanipour, E., Valsecchi, N., Kapoor, S., Cicinelli, M. V., & Chhablani, J. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.01.010 · Cited by 23
Katogiannis, K., Thymis, J., Kousathana, F., Pavlidis, G., Korakas, E., Kountouri, A., Balampanis, K., Prentza, V., Kostelli, G., Michalopoulou, H., et al. (2024) · Medicina · doi:10.3390/medicina60030395 · Cited by 29
“Studies also support that both GLP1 and SGLT2 may improve endothelial function [16,32,34].”
BackgroundScholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Pujadas, G., Nigris, V. D., Sala, L. L., Testa, R., Genovese, S., & Ceriello, A. (2015) · Endocrine · doi:10.1007/s12020-015-0799-z · Cited by 17
“Nevertheless, the GLP-1 signaling cascade is more complex, as other pathways can also be activated [10, 22, 23].”
BackgroundGliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients
Kosi‐Trebotic, L., Thomas, A., Harreiter, J., Chmelík, M., Trattnig, S., & Kautzky‐Willer, A. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12817 · Cited by 15
Blaslov, K., Bulum, T., & Duvnjak, L. S. (2015) · European Journal of Ophthalmology · doi:10.5301/ejo.5000547 · Cited by 11
“In addition, more homogenecity with human GLP-1 seems to provide a better effect (14, 24, 29, 30).”
BackgroundExamining the Role of Insulin in the Regulation of Cardiovascular Health
Salt, I. P. (2012) · Future Cardiology · doi:10.2217/fca.12.77 · Cited by 11
“It is becoming apparent that these drugs also have direct effects on myocardial and endothelial cells including stimulation of NO and suppression of proinflammatory signaling [84,85].”
BackgroundSui, C., Liu, F., Tang, L., Li, X., Zhou, Y., Yin, H., & Ai, S. (2018) · Microchimica Acta · doi:10.1007/s00604-018-3076-z · Cited by 11
Chen, B., Zhou, W., Zhao, W., Yuan, P., Tang, C., Wang, G., Leng, J., Ma, J., Wang, X., Hui, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10497 · Cited by 11
Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain
Kim, Y., & Song, J. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa080 · Cited by 9
The ocular surface in type 2 diabetes: pathophysiology and impact of anti-diabetic drugs
Singh, I., Poynten, A. M., Krishnan, A. V., Willcox, M. D. P., & Markoulli, M. P. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101417 · Cited by 10
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
“GLP1As have been shown to slow the progression of atherosclerosis [22].”
Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin
Pfützner, A., Pfützner, A. H., Kann, P. H., & Burgard, G. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663745 · Cited by 5
Self-citationAsemi, Z., Salami, R., Salami, M., Mafi, A., Aarabi, M. H., & Vakili, O. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220829102020 · Cited by 7
Suratkal, J. P., D'Silva, T., & AlHilli, M. M. (2025) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2025.101718 · Cited by 3
“Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as a treatment for T2D, offering effective glycemic control while also improving lipid profiles, promoting weight loss, and enhancing insulin sensitivity (He et al., 2016; Forst et al., 2012).”
Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.
CHANG, C., Yang, T.-F., Lee, T.-I., Chen, Y., Kao, Y., Chen, S., & Chen, Y. (2014) · Europe PMC (PubMed Central) · Cited by 2
Akpan, N., Zhou, B., Rasu, R. S., & Sambamoorthi, U. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.1.14 · Cited by 2
Marzook, F. A., Kesaria, A. A., Glover, J. M., & Alijanipour, P. (2026) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000002113 · Cited by 2
The Skeletal Muscle Microvasculature and Its Effects on Metabolism
Kolka, C. M. (2016) · InTech eBooks · doi:10.5772/63535 · Cited by 3
“GLP‐1 receptor agonists have beneficial effects on the vasculature [74–78] and metabolism of glucose [70, 71, 79–81]; though whether this reflects a direct effect on glucose metabolism, an indirect effect through blood flow changes, or a combination of these is not clear.”
BackgroundSala, L. L., Genovese, S., & Ceriello, A. (2017) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000494 · Cited by 1
“Besides its key role in the regulation of insulin secretion and glucose homeostasis [1], GLP-1 is also emerging as an important player in the protection of kidney and cardiovascular system [2-4].”
BackgroundPossible Protective Mechanisms of Sitagliptin against Isoproternol Induced Myocardial Injury in Rat
El‐Bakly, W. M. (2015) · Ain Shams Journal of Forensic Medicine and Clinical Toxicology · doi:10.21608/ajfm.2015.18653 · Cited by 1
“expressed in the heart and vasculature with specific localization in vascular endothelium/smooth muscle, endocardium and cardiomyocytes, suggesting that GLP-1 may play an important role in the cardiovascular system (Forst et al., 2012).”
BackgroundAhmed, S., & Hussein, R. H. (2023) · Journal of Zankoy Sulaimani - Part A · doi:10.17656/jzs.10931
Modern perspective on the features and risk factors of erectile dysfunction in older men
Ibodzoda, N. S., Бадридинович, Ф. М., & Najmidinov, K. N. (2026) · Health care of Tajikistan · doi:10.52888/0514-2515-2025-367-4-135-143
Metadata
- Authors
- Forst, T., Weber, M. M., & Pfützner, A.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Institute for Clinical Research and Development, 55116 Mainz, Germany
- Corresponding author
- Forst, Thomas
- Venue
- Experimental Diabetes Research
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-9
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3345223
- OpenAlex
- W2102467882
- Cited by
- 44
- References
- 91
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 2 · 2013: 6 · 2012: 2
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, incretin-based therapy, endothelial dysfunction, vascular dysfunction, cardiovascular risk, cardiovascular mortality, beta-cell dysfunction
- MeSH terms
- Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.